Literature DB >> 25975638

Design, synthesis and biological evaluation of bivalent benzoxazolone and benzothiazolone ligands as potential anti-inflammatory/analgesic agents.

Ahmed H Abdelazeem1, Shabana I Khan2, Stephen W White3, Kenneth J Sufka4, Christopher R McCurdy5.   

Abstract

Benzoxazolone and benzothiazolone were used as template blocks to develop two series of dimers as anti-inflammatory and analgesic agents based on the concept of bivalent ligands. The first series (I) involved varying the carbon chain lengths extending from the piperazine core to the nitrogen atom of the dibenzo[d]oxazol-2(3H)-one or dibenzo[d]thiazol-2(3H)-one. The second series (II) was designed by changing the attachment point. All compounds were screened for their in vitro anti-inflammatory activity in terms of the inhibition of inducible nitric oxide synthase (iNOS) and nuclear factor kappa B (NF-κB). Seventeen compounds inhibited both targets. Eleven of them exhibited IC50 values below 3μM while five compounds showed IC50 values of 1μM or below. Most of the compounds were found to be devoid of cytotoxicity against mammalian kidney and solid tumors cell lines up to 25μg/mL. In vivo anti-inflammatory and antinociceptive studies revealed that compounds 3j, 5t and 8b have significant anti-inflammatory and analgesic activity comparable to that of indomethacin and ketorolac, respectively.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-inflammatory/analgesic; Benzothiazolone; Benzoxazolone; Dimers; NF-κB; Nociception; Piperazine; iNOS

Mesh:

Substances:

Year:  2015        PMID: 25975638      PMCID: PMC4467529          DOI: 10.1016/j.bmc.2015.04.057

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  33 in total

1.  NO pain: potential roles of nitric oxide in neuropathic pain.

Authors:  Dan Levy; Douglas W Zochodne
Journal:  Pain Pract       Date:  2004-03       Impact factor: 3.183

Review 2.  Nuclear factor-kappaB in cancer development and progression.

Authors:  Michael Karin
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

Review 3.  NF-kappaB activation in development and progression of cancer.

Authors:  Jun-Ichiro Inoue; Jin Gohda; Taishin Akiyama; Kentaro Semba
Journal:  Cancer Sci       Date:  2007-03       Impact factor: 6.716

4.  Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOS dimerization inhibitors that are orally active in pain models.

Authors:  Joseph E Payne; Céline Bonnefous; Kent T Symons; Phan M Nguyen; Marciano Sablad; Natasha Rozenkrants; Yan Zhang; Li Wang; Nahid Yazdani; Andrew K Shiau; Stewart A Noble; Peter Rix; Tadimeti S Rao; Christian A Hassig; Nicholas D Smith
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

Review 5.  A cytokine-mediated link between innate immunity, inflammation, and cancer.

Authors:  Wan-Wan Lin; Michael Karin
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

6.  Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase.

Authors:  Catherine E Trebino; Jeffrey L Stock; Colleen P Gibbons; Brian M Naiman; Timothy S Wachtmann; John P Umland; Karamjeet Pandher; Jean-Martin Lapointe; Sipra Saha; Marsha L Roach; Demetrius Carter; Nathalie A Thomas; Becky A Durtschi; John D McNeish; John E Hambor; Per-Johan Jakobsson; Thomas J Carty; Jose R Perez; Laurent P Audoly
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-30       Impact factor: 11.205

Review 7.  NF-kappaB as a potential molecular target for cancer therapy.

Authors:  Chae Hyeong Lee; Yong-Tark Jeon; Su-Hyeong Kim; Yong-Sang Song
Journal:  Biofactors       Date:  2007       Impact factor: 6.113

8.  Computer-aided discovery of anti-inflammatory thiazolidinones with dual cyclooxygenase/lipoxygenase inhibition.

Authors:  Athina A Geronikaki; Alexey A Lagunin; Dimitra I Hadjipavlou-Litina; Phaedra T Eleftheriou; Dmitrii A Filimonov; Vladimir V Poroikov; Intekhab Alam; Anil K Saxena
Journal:  J Med Chem       Date:  2008-02-27       Impact factor: 7.446

9.  Spinal NF-kB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity.

Authors:  Kyung-Min Lee; Bong-Seok Kang; Hye-Lim Lee; Sun-Joo Son; Sung-Hun Hwang; Dong-Sun Kim; Jae-Sik Park; Hee-Jung Cho
Journal:  Eur J Neurosci       Date:  2004-06       Impact factor: 3.386

10.  Effusanin E suppresses nasopharyngeal carcinoma cell growth by inhibiting NF-κB and COX-2 signaling.

Authors:  Mingzhu Zhuang; Mouming Zhao; Huijuan Qiu; Dingbo Shi; Jingshu Wang; Yun Tian; Lianzhu Lin; Wuguo Deng
Journal:  PLoS One       Date:  2014-10-21       Impact factor: 3.240

View more
  1 in total

1.  Synthesis of Various 2-Aminobenzoxazoles: The Study of Cyclization and Smiles Rearrangement.

Authors:  Veronika Šlachtová; Jan Chasák; Lucie Brulíková
Journal:  ACS Omega       Date:  2019-11-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.